{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:36:42Z","timestamp":1793176602046,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015849","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000}}],"reference-count":234,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015849.pub2","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:33:31Z","timestamp":1739860411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes"],"prefix":"10.1002","volume":"2025","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Kanazawa University; Kanazawa Japan"},{"name":"Innovative Clinical Research Center; Kanazawa University; Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"},{"name":"Nephrology, Dialysis and Transplantation Unit; Department of Medical and Surgical Sciences, University of Foggia; Foggia Italy"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"22","key":"10.1002\/14651858.CD015849.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMc2115776","article-title":"Efpeglenatide and heart and kidney outcomes in type 2 diabetes","volume":"385","author":"Borderie","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/dom.14223","article-title":"Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist","volume":"23","author":"Gerstein","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"13","key":"10.1002\/14651858.CD015849.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.122.063716","article-title":"Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial","volume":"147","author":"Gerstein","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015849.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"i331","DOI":"10.1093\/ndt\/gfac070.076","article-title":"Change in KDIGO kidney risk category with semaglutide treatment-a post hoc analysis of the Sustain 6 trial [abstract no: MO462]","volume":"37","author":"Tuttle","year":"2022","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0006|cit6","first-page":"9","article-title":"CKD outcomes in type 2 diabetes and moderate-to-severe CKD treated with dulaglutide versus insulin glargine: AWARD-7 [abstract no: TH-OR033]","volume":"29","author":"Tuttle","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0007|cit7","first-page":"S3","article-title":"Comparable glycaemic control with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and chronic kidney disease (AWARD-7) [abstract no: 2]","volume":"60","author":"Tuttle","year":"2017","journal-title":"Diabetologia"},{"issue":"Supp1","key":"10.1002\/14651858.CD015849.pub2-BIB0008|cit8","article-title":"Comparable glycemic control, greater weight loss, and lower hypoglycemia with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and moderate to severe chronic kidney disease (AWARD-7) [abstract no: A71]","volume":"10","author":"Tuttle","year":"2018","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0011|cit11","first-page":"102","article-title":"Clinical events in type 2 diabetes and moderate-to-severe CKD by albuminuria status: dulaglutide vs. insulin glargine [abstract no: SA-OR081]","volume":"30","author":"Tuttle","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1007\/s00125-019-4946-6","article-title":"Chronic kidney disease (CKD) outcomes with dulaglutide (DU) versus insulin glargine (IG) in type 2 diabetes and moderate-to-severe CKD by albuminuria status: AWARD-7 [abstract no: PS 082]","volume":"62","author":"Tuttle","year":"2019","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1007\/s00125-023-05969-6","article-title":"Dulaglutide and glomerular hyperfiltration and albuminuria in youth with type 2 diabetes: results from the AWARD-PEDS study [abstract no: 709]","volume":"66","author":"Bjornstad","year":"2023","journal-title":"Diabetologia"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dc24-0322","article-title":"Dulaglutide and glomerular hyperfiltration, proteinuria, and albuminuria in youth with type 2 diabetes: post hoc analysis of the AWARD-PEDS study","volume":"47","author":"Bjornstad","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.jrn.2020.09.006","article-title":"The effect of glycemic control on renal triglyceride content assessed by proton spectroscopy in patients with type 2 diabetes mellitus: a single-center parallel-group trial","volume":"31","author":"Dekkers","year":"2021","journal-title":"Journal of Renal Nutrition"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0018|cit18","first-page":"53","article-title":"Insulin degludec\/liraglutide is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: Analyses from phase 3 trials [abstract]","volume":"12","author":"Di Bartolo","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","article-title":"Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)","volume":"37","author":"Buse","year":"2014","journal-title":"Diabetes Care"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0021|cit21","first-page":"53","article-title":"Insulin degludec\/liraglutide is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: Analyses from phase 3 trials [abstract]","volume":"12","author":"Di Bartolo","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0022|cit22","first-page":"53","article-title":"Insulin degludec\/liraglutide is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: analyses from phase 3 trials [abstract]","volume":"12","author":"Di Bartolo","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Therapy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0024|cit24","first-page":"53","article-title":"Insulin degludec\/liraglutide is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: analyses from phase 3 trials [abstract]","volume":"12","author":"Di Bartolo","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dme.13256","article-title":"Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial","volume":"34","author":"Rodbard","year":"2017","journal-title":"Diabetic Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0026|cit26","first-page":"53","article-title":"Insulin degludec\/liraglutide is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: Analyses from phase 3 trials [abstract]","volume":"12","author":"Di Bartolo","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ahj.2015.02.002","article-title":"Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo","volume":"169","author":"Bentley-Lewis","year":"2015","journal-title":"American Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0029|cit29","first-page":"A280","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes-a post-hoc analysis of the ELIXA trial [abstract no: 1060-P]","volume":"67","author":"Muskiet","year":"2018","journal-title":"Diabetes"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"23","key":"10.1002\/14651858.CD015849.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1631263","DOI":"10.1155\/2018\/1631263","article-title":"Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration","volume":"2018","author":"Seferovic","year":"2018","journal-title":"Journal of Diabetes Research"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e004743","DOI":"10.1161\/JAHA.116.004743","article-title":"Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus","volume":"6","author":"Wolsk","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0035|cit35","first-page":"A138","article-title":"Renal outcomes in the exenatide study of cardiovascular event lowering (EXSCEL) [abstract no: 522-P]","volume":"67","author":"Bethel","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.17139","article-title":"Angiopoietin 2 independently predicts heart failure hospitalization and is beneficially modified by GLP1RA: results from the EXSCEL trial [abstract no: 17139]","volume":"148","author":"Harrington","year":"2023","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1007\/s00125-018-4693-0","article-title":"Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) [abstract no: 73]","volume":"61","author":"Hernandez","year":"2018","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","article-title":"Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","volume":"174","author":"Holman","year":"2016","journal-title":"American Heart Journal"},{"issue":"13","key":"10.1002\/14651858.CD015849.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/dom.13958","article-title":"Prediction and validation of exenatide risk marker effects on progression of renal disease: insights from EXSCEL","volume":"22","author":"Idzerda","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","article-title":"Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"187","author":"Mentz","year":"2017","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1007\/s00125-019-4946-6","article-title":"Exenatide once weekly in diabetes patients with stage 2\/3 chronic kidney disease: a pooled 6-month analysis [abstract no: 755]","volume":"62","author":"Sjostrom","year":"2019","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD015849.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/dom.14175","article-title":"Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial","volume":"22","author":"Aart-van der Beek","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/ndt\/gfad252","article-title":"Erratum: the rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease (Nephrology Dialysis Transplantation (2023) 38: 9 (2041-2051) DOI: 10.1093\/ndt\/gfad009)","volume":"39","year":"2024","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 66","key":"10.1002\/14651858.CD015849.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/eurheartj\/ehac544.2617","article-title":"Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial [abstract]","volume":"60","author":"Mahaffey","year":"2022","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"00","author":"Mahaffey","year":"2024","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"24","author":"Mann","year":"2024","journal-title":"Nature Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015849.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"i893","DOI":"10.1093\/ndt\/gfac126.002","article-title":"Baseline characteristics of the flow trial population: kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease [abstract no: FC123]","volume":"37","author":"Perkovic","year":"2022","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2337\/db22-747-P","article-title":"Baseline characteristics of subjects in the once-weekly (OW) semaglutide FLOW kidney outcomes trial [abstract no: 747-P]","volume":"71","author":"Pratley","year":"2022","journal-title":"Diabetes"},{"issue":"17","key":"10.1002\/14651858.CD015849.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1530-891X(20)47084-3","article-title":"Efficacy and safety of lixisenatide as add-on in patients with T2D aged >=70 years uncontrolled on basal insulin in the GetGoal-O study [abstract no: 238]","volume":"24","author":"Dailey","year":"2018","journal-title":"Endocrine Practice"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/dom.12986","article-title":"Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment","volume":"19","author":"Hanefeld","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","volume":"15","author":"Pinget","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD015849.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"Journal of Diabetes & its Complications"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/dmrr.2541","article-title":"Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)","volume":"30","author":"Yu Pan","year":"2014","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"12","key":"10.1002\/14651858.CD015849.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes","volume":"387","author":"Nathan","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamainternmed.2023.1487","article-title":"Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial","volume":"183","author":"Wexler","year":"2023","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"American Heart Journal"},{"issue":"10157","key":"10.1002\/14651858.CD015849.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000510613","article-title":"The glycemic effect of liraglutide evaluated by continuous glucose monitoring in persons with type 2 diabetes receiving dialysis","volume":"145","author":"Bomholt","year":"2020","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"i492","DOI":"10.1093\/ndt\/gfy104.SP426","article-title":"Hypoglycaemic episodes evaluated by continuous glucose monitoring in patients with type 2 diabetes and dialysis-dependent end-stage renal disease randomised to 12-week liraglutide or placebo treatment [abstract no: SP426]","volume":"33","author":"Bomholt","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e002764","DOI":"10.1136\/bmjopen-2013-002764","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study","volume":"3","author":"Idorn","year":"2013","journal-title":"BMJ Open"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0070|cit70","first-page":"S370","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, randomised, placebo-controlled trial [abstract no: 909]","volume":"57","author":"Idorn","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/dom.12444","article-title":"LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations","volume":"17","author":"Daniels","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0074|cit74","first-page":"S8","article-title":"Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract no: PS04]","volume":"58","author":"Mann","year":"2017","journal-title":"Internist"},{"issue":"25","key":"10.1002\/14651858.CD015849.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD015849.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1161\/CIRCULATIONAHA.119.040419","article-title":"Response by Mann et al to Letter regarding article, \"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial","volume":"139","author":"Mann","year":"2019","journal-title":"Circulation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0077|cit77","first-page":"575","article-title":"Safety of liraglutide versus placebo in patients with T2D and CKD in LEADER the trial [abstract no: FR-PO668]","volume":"28","author":"Mann","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0079|cit79","first-page":"111","article-title":"Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract no: A251]","volume":"10","author":"Mann","year":"2018","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0080|cit80","first-page":"1B","article-title":"Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial [abstract no: HI-OR01]","volume":"27","author":"Mann","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0081|cit81","first-page":"1091","article-title":"Renal function decline in type 2 diabetes: post hoc analysis of LEADER [abstract no:PUB069]","volume":"30","author":"Mann","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0085|cit85","first-page":"540","article-title":"Increasing baseline albuminuria is associated with a continuously increased risk of cardiovascular (CV) and renal outcomes in the LEADER trial [abstract no: FR-PO462]","volume":"29","author":"Mosenzon","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/dom.14126","article-title":"Cardiovascular and renal outcomes by baseline albuminuria status and renal function: results from the LEADER randomized trial","volume":"22","author":"Mosenzon","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0087|cit87","first-page":"9","article-title":"Reduction in albuminuria is associated with cardiorenal protection independent of baseline albuminuria-a post hoc analysis of the LEADER trial [abstract no: TH-OR034]","volume":"29","author":"Persson","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0089|cit89","first-page":"1091","article-title":"Individual effects of liraglutide on cardiorenal risk markers: Results from the LEADER trial [abstract no: PUB071]","volume":"30","author":"Persson","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/HJH.0000000000000890","article-title":"LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial","volume":"34","author":"Petrie","year":"2016","journal-title":"Journal of Hypertension"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0091|cit91","first-page":"S546","article-title":"LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: Baseline data from the trial [abstract no: 1138]","volume":"58","author":"Petrie","year":"2015","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"S38-9","DOI":"10.1007\/s00125-018-4693-0","article-title":"Liraglutide reduces major cardiovascular events in patients with chronic kidney disease: results from the LEADER trial [abstract no: 74]","volume":"61","author":"Poulter","year":"2018","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0093|cit93","first-page":"23","article-title":"Liraglutide and renal outcomes in Type 2 diabetes: Results of the 'liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results' (LEADER) trial [abstract no: A52]","volume":"34","author":"Poulter","year":"2017","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-016-0153-5","article-title":"LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ","volume":"8","author":"Rutten","year":"2016","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jdiacomp.2016.06.001","article-title":"LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population","volume":"30","author":"Satman","year":"2016","journal-title":"Journal of Diabetes and Its Complications"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0096|cit96","first-page":"206","article-title":"Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial [abstract no: 11N.11]","volume":"24","author":"Sesti","year":"2017","journal-title":"High Blood Pressure & Cardiovascular Prevention"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","article-title":"LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial","volume":"43","author":"Steinberg","year":"2014","journal-title":"Pancreas"},{"issue":"22","key":"10.1002\/14651858.CD015849.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"e1015","DOI":"10.1161\/CIRCULATIONAHA.118.039071","article-title":"Letter by Xie et al Regarding article, \"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial\"","volume":"139","author":"Xie","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc17-2677","article-title":"Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience","volume":"41","author":"Zinman","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman","year":"2018","journal-title":"Diabetes Therapy"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1681\/ASN.20203110S1337c","article-title":"The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER trial [abstract no: PO0984]","volume":"31","author":"Zobel","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/dom.14578","article-title":"The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials","volume":"24","author":"Zobel","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0105|cit105","first-page":"S361","article-title":"HARMONY 8: once-weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment: week 26 results [abstract no: 906]","volume":"56","author":"Leiter","year":"2013","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/dom.13682","article-title":"Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting","volume":"21","author":"Unger","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8227(14)70266-9","article-title":"Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial [abstract no: OP60]","volume":"106","author":"Mathieu","year":"2014","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jcjd.2014.07.020","article-title":"Efficacy and safety of liraglutide vs. placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL) [abstract no: 18]","volume":"38","author":"Ngo","year":"2014","journal-title":"Canadian Journal of Diabetes"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0111|cit111","first-page":"550A","article-title":"Efficacy and safety of liraglutide versus placebo by age subgroup in subject with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial [abstract no: FR-PO791]","volume":"25","author":"Scott","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0112|cit112","first-page":"75A","article-title":"Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial [abstract no: FR-OR122]","volume":"25","author":"Scott","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0113|cit113","first-page":"S84","article-title":"Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial [abstract no: 182]","volume":"57","author":"Umpierrez","year":"2014","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/dom.13638","article-title":"Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment","volume":"21","author":"Zobel","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.12669\/pjms.38.5.4719","article-title":"Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN)","volume":"38","author":"Liu","year":"2022","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0116|cit116","first-page":"144","article-title":"Clinical efficacy and safety of liraglutide and dapagliflozin on glucose and lipid metabolism and insulin function in patients with type 2 diabetes mellitus","volume":"30","author":"Ma","year":"2024","journal-title":"Alternative Therapies in Health & Medicine"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.diabres.2019.05.001","article-title":"Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial","volume":"153","author":"Muskiet","year":"2019","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0118|cit118","first-page":"64","article-title":"The effect of low dose liraglutide on renal inflammation in type 2 diabetic kidney disease: a randomised controlled study [abstract no: 101]","volume":"33","author":"Neff","year":"2016","journal-title":"Diabetic Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.20203110S1348b","article-title":"Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, for patients with type 2 diabetes mellitus and CKD [abstract no: PO1018]","volume":"31","author":"Parker","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2337\/db21-674-P","article-title":"Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist in patients with T2DM and DKD [abstract no: 675-P]","volume":"70","author":"Parker","year":"2021","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"3","key":"10.1002\/14651858.CD015849.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dom.13553","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function-related outcomes in Type 2 diabetes: a REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-020-01179-1","article-title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","volume":"19","author":"Dagenais","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.13028","article-title":"Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide","volume":"20","author":"Gerstein","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"10193","key":"10.1002\/14651858.CD015849.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10193","key":"10.1002\/14651858.CD015849.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.20203110S1348a","article-title":"Dulaglutide and kidney function-related outcomes in type 2 diabetes: Post hoc analysis from the REWIND trial [abstract no: PO1017]","volume":"31","author":"Shaw","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1007\/s00125-023-05969-6","article-title":"Efficacy of cotadutide dual GLP1-glucagon receptor agonist on albuminuria and glycaemic control in patients with diabetic kidney disease [abstract no: 58]","volume":"66","author":"Robertson","year":"2023","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"i87","DOI":"10.1093\/ndt\/gfad063a_3000","article-title":"Efficacy and safety of cotadutide, a dual GLP1-glucagon receptor agonist, in patients with chronic kidney disease and T2DM [abstract no: 3000]","volume":"38","author":"Selvarajah","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0138|cit138","first-page":"S32","article-title":"Efficacy of cotadutide dual GLP1-glucagon receptor agonist on albuminuria and glycaemic control in patients with diabetic kidney disease [abstract no: 58]","volume":"66","author":"Robertson","year":"2023","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney International"},{"issue":"Supp 1","key":"10.1002\/14651858.CD015849.pub2-BIB0140|cit140","first-page":"i87","article-title":"Efficacy and safety of cotadutide, a dual GLP1-glucagon receptor agonist, in patients with chronic kidney disease and T2DM [abstract no: 3000]","volume":"38","author":"Selvarajah","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"108673","DOI":"10.1016\/j.jdiacomp.2023.108673","article-title":"The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: a prespecified, secondary analysis from a randomized, clinical trial","volume":"38","author":"Gullaksen","year":"2024","journal-title":"Journal of Diabetes & its Complications"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s00125-024-06228-y","article-title":"Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial","volume":"67","author":"Vernstrom","year":"2024","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1007\/s00125-023-05969-6","article-title":"Renal effects of empagliflozin alone or in combination with semaglutide in albuminuric type 2 diabetes: a randomised, placebo-controlled trial [abstract no: 235]","volume":"66","author":"Sivalingam","year":"2023","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","article-title":"Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study","volume":"26","author":"Sivalingam","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae150","article-title":"Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6","volume":"pre-publication","author":"Apperloo","year":"2024","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0148|cit148","first-page":"S4","article-title":"Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6) [abstract no: 4]","volume":"60","author":"Consoli","year":"2017","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0149|cit149","first-page":"S80","article-title":"Semaglutide treatment and renal function in the SUSTAIN 6 trial [abstract]","volume":"14","author":"Jacob","year":"2019","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"19","key":"10.1002\/14651858.CD015849.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0153|cit153","first-page":"1175A","article-title":"Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk [abstract no: 2220]","volume":"66","author":"Sanyal","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1007\/s00125-018-4693-0","article-title":"Semaglutide treatment and renal function in the SUSTAIN 6 trial [abstract no: 78]","volume":"61","author":"Silver","year":"2018","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"i145","DOI":"10.1093\/ndt\/gfad063b_4441","article-title":"Kidney disease outcomes with semaglutide versus placebo across baseline KDIGO risk categories: a post hoc analysis of SUSTAIN 6 [abstract no: 4441]","volume":"38","author":"Tuttle","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"KI Reports"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1007\/s00125-019-4946-6","article-title":"Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials","volume":"62","author":"Verma","year":"2019","journal-title":"Diabetologia"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1111\/dom.15860","article-title":"Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01183-5","article-title":"Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial","volume":"20","author":"Tuttolomondo","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/dom.15033","article-title":"Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study","volume":"25","author":"Aart-van der Beek","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"S387","DOI":"10.1007\/s00125-022-05755-w","article-title":"Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomised crossover clinical trial [abstract no: 750]","volume":"65","author":"Aart-van der Beek","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"Von Scholten","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: a randomized clinical trial","volume":"19","author":"Scholten","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015849.pub2-BIB0166|cit166","first-page":"555A","article-title":"Renal effects of liraglutide in type 2 diabetic patients with albuminuria: a randomized clinical trial [abstract no: FR-PO815]","volume":"27","author":"Scholten","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0167|cit167","first-page":"i372","article-title":"Short term hemodynamic effect of the GLP 1 analogue-liraglutide in patients with diabetic nephropathy [abstract no: SP081]","volume":"33","author":"Wajdlich","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1038\/s41598-024-55724-z","article-title":"The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function","volume":"14","author":"Wajdlich","year":"2024","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3760\/cma.j.cn115791-20210922-00507","article-title":"Renal efficacy of exenatide in diabetic kidney disease patients with different baseline renal function","volume":"14","author":"Jimin","year":"2022","journal-title":"Chinese Journal of Diabetes Mellitus"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000510255","article-title":"Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease","volume":"51","author":"Wang","year":"2020","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000337929","article-title":"Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria","volume":"35","author":"Zhang","year":"2012","journal-title":"Kidney & Blood Pressure Research"},{"issue":"6","key":"10.1002\/14651858.CD015849.pub2-BIB0172|cit172","first-page":"967","article-title":"Renal protection of exenatide in patients with diabetic kidney disease in early stage","volume":"40","author":"Zhou","year":"2019","journal-title":"Journal of Xi'an Jiaotong University (Medical Sciences)"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)","volume":"36","author":"Ahren","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD015849.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabetic Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0176|cit176","unstructured":"Effect of ultra-short-term insulin therapy combined with once-weekly semaglutide in clinical remission in middle-aged and elderly patients with type 2 diabetes mellitus: an open-label, randomised controlled trial trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200059717"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0177|cit177","unstructured":"A randomized, controlled trial to evaluate the improvement of oxidative stress levels and renal function in patients with diabetic kidney disease treated with semaglutide for 28 weeks trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2400080751"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0178|cit178","unstructured":"A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD) https:\/\/clinicaltrials.gov\/study\/NCT05536804"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0179|cit179","unstructured":"Renoprotective effects of dulaglutide in patients with type 2 diabetic nephropathy https:\/\/clinicaltrials.gov\/study\/NCT06182891"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0180|cit180","unstructured":"Semaglutide's effect on renal hemodynamics and function in patients with type 2 diabetes mellitus and nephropathy (SEMA-RMA) https:\/\/clinicaltrials.gov\/study\/NCT06555146"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0181|cit181","unstructured":"An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL-OMON46820"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13063-024-07930-3","article-title":"Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)","volume":"25","author":"Al-Ozairi","year":"2024","journal-title":"Trials [electronic Resource]"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015849.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"i290","DOI":"10.1093\/ndt\/gfac070.013","article-title":"REMODEL: A mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease","volume":"37","author":"Bjornstad","year":"2022","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD015849.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"e15377","DOI":"10.1111\/dme.15377","article-title":"Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): study protocol of a phase 2 double-blinded randomised placebo-controlled trial","volume":"41","author":"Frampton","year":"2024","journal-title":"Diabetic Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0186|cit186","unstructured":"ANZDATA 41st Annual Report 2018 (Data to 2017) https:\/\/www.anzdata.org.au\/report\/anzdata-41st-annual-report-2018-anzdata\/"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-020-01311-5","article-title":"Health-related quality of life and associated factors among patients with diabetes mellitus at the University of Gondar referral hospital","volume":"18","author":"Aschalew","year":"2020","journal-title":"Health & Quality Life Outcomes"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/dom.14702","article-title":"Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis","volume":"24","author":"Cao","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"10085","key":"10.1002\/14651858.CD015849.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes [Erratum in: Lancet. 2017 Jun 3;389(10085):2192]","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015849.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015849.pub2-BIB0191|cit191","first-page":"S1","article-title":"Excerpts from the United States Renal Data System 2007 annual data report","volume":"51","author":"Collins","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015849.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2337\/dbi18-0008","article-title":"The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications","volume":"67","author":"Drucker","year":"2018","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0195|cit195","unstructured":"Eldridge S Campbell M Campbell M Dahota A Giraudeau B Higgins J RoB 2 for cluster-randomized trials https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/rob-2-for-cluster-randomized-trials (accessed 16 January 2025)"},{"issue":"3-4","key":"10.1002\/14651858.CD015849.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Review of Diabetic Studies"},{"issue":"10159","key":"10.1002\/14651858.CD015849.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"7650","key":"10.1002\/14651858.CD015849.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0200|cit200","unstructured":"GRADEpro GDT McMaster University (Developed by Evidence Prime) 2024"},{"issue":"7","key":"10.1002\/14651858.CD015849.pub2-BIB0201|cit201","first-page":"1467","article-title":"Safety and efficacy of exenatide once weekly in participants with type 2 diabetes and stage 2\/3 chronic kidney disease","volume":"11","author":"Guja","year":"2020","journal-title":"Diabetes Therapy Research, Treatment & Education of Diabetes & Related Disorders"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD015849.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0204|cit204","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0205|cit205","unstructured":"Higgins JP Savovi J Page MJ Elbers RG Sterne JA Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0206|cit206","unstructured":"Higgins JP Eldridge S Li T Chapter 23: including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41100-018-0183-6","article-title":"Annual dialysis data report 2016, JSDT Renal Data Registry","volume":"4","author":"Masakane","year":"2018","journal-title":"Renal Replacement Therapy"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0209|cit209","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO Working Group","year":"2012","journal-title":"Kidney International Supplements"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0210|cit210","doi-asserted-by":"crossref","unstructured":"KDIGO Working Group KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease https:\/\/kdigo.org\/wp-content\/uploads\/2022\/10\/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf","DOI":"10.22141\/2307-1257.10.4.2021.247896"},{"issue":"12","key":"10.1002\/14651858.CD015849.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis","volume":"42","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD015849.pub2-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ecl.2017.10.006","article-title":"Managing diabetes and cardiovascular risk in chronic kidney disease patients","volume":"47","author":"Lovre","year":"2018","journal-title":"Endocrinology & Metabolism Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD015849.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"24","key":"10.1002\/14651858.CD015849.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD015849.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/jcm10050985","article-title":"Clinical effectiveness and safety of once-weekly GLP-1 receptor agonist dulaglutide as add-on to metformin or metformin plus insulin secretagogues in obesity and type 2 diabetes","volume":"10","author":"Mirabelli","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"e001258","DOI":"10.1136\/bmjgh-2018-001258","article-title":"The costs of diabetes treatment in low- and middle-income countries: a systematic review","volume":"4","author":"Moucheraud","year":"2019","journal-title":"BMJ Global Health"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0219|cit219","first-page":"m4572","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials [Erratum in: BMJ. 2022 Jan 18;376:o109]","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015849.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4065\/83.12.1373","article-title":"Rationale and strategies for early detection and management of diabetic kidney disease","volume":"83","author":"Radbill","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"19","author":"Raghavan","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Research & Clinical Practice"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0223|cit223","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0224|cit224","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0225|cit225","unstructured":"The SONG Handbook Version 1.0 https:\/\/songinitiative.org\/reports-and-publications\/"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technology & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD015849.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0229|cit229","unstructured":"United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018 https:\/\/www.niddk.nih.gov\/about-niddk\/strategic-plans-reports\/usrds\/prior-data-reports\/2018"},{"key":"10.1002\/14651858.CD015849.pub2-BIB0230|cit230","unstructured":"World Health Organization Diabetes https:\/\/www.who.int\/health-topics\/diabetes"},{"issue":"1","key":"10.1002\/14651858.CD015849.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13300-020-00798-x","article-title":"The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes","volume":"11","author":"Yin","year":"2020","journal-title":"Diabetes Therapy"},{"issue":"15","key":"10.1002\/14651858.CD015849.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD015849.pub2-BIB0234|cit234","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015849","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","author":"Natale","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:05:00Z","timestamp":1793174700000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015849.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":234,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015849.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}